Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$521M |
| 2 |
Nike
NKE
|
+$509M |
| 3 |
Micron Technology
MU
|
+$439M |
| 4 |
Super Micro Computer
SMCI
|
+$435M |
| 5 |
Broadcom
AVGO
|
+$329M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$5.31B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.89B |
| 3 |
Amazon
AMZN
|
+$1.48B |
| 4 |
Microsoft
MSFT
|
+$1.07B |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$904M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 2.38% |
| 2 | Consumer Discretionary | 1.03% |
| 3 | Financials | 0.75% |
| 4 | Healthcare | 0.67% |
| 5 | Communication Services | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FLZH
11476
Flash Sports & Media Holdings
FLZH
$5.45M
| $34.1K | ﹤0.01% |
+1,027
| New | +$40.9K |
|
|
RAPT
11477
DELISTED
RAPT Therapeutics
RAPT
| $34K | ﹤0.01% |
1,392
-6,355
| -82% | -$294K |
|
11478
ASP Isotopes
ASPI
$604M
| $33.4K | ﹤0.01% |
+10,923
| New | +$42.1K |
|
|
NWGL
11479
CL Workshop Group Ltd
NWGL
$14M
| $33K | ﹤0.01% |
+19,387
| New | +$121K |
|
11480
Bionano Genomics
BNGO
$14.3M
| $32.8K | ﹤0.01% |
807
-450
| -36% | -$24.7K |
|
11481
CALL
AgEagle Aerial Systems
UAVS
$69.2M
| $32.6K | ﹤0.01% |
1,306
+1,106
| +553% | +$36.1K |
|
11482
CALL
Aveanna Healthcare
AVAH
$2.97B
| $32.6K | ﹤0.01% |
11,800
-1,000
| -8% | -$2.49K |
|
11483
CALL
Tenaya Therapeutics
TNYA
$156M
| $32.5K | ﹤0.01% |
10,500
-4,100
| -28% | -$16.9K |
|
11484
CALL
Butterfly Network
BFLY
$2.3B
| $32.4K | ﹤0.01% |
38,600
-35,700
| -48% | -$33.3K |
|
11485
Fortress Biotech
FBIO
$93.7M
| $32.2K | ﹤0.01% |
+18,851
| New | +$34.2K |
|
|
EMX
11486
DELISTED
EMX Royalty
EMX
| $32.2K | ﹤0.01% |
+17,884
| New | +$34K |
|
11487
CALL
NanoViricides
NNVC
$32.7M
| $32.2K | ﹤0.01% |
+18,700
| New | +$33.3K |
|
|
SBFM
11488
Sunshine Biopharma
SBFM
$4.81M
| $32.1K | ﹤0.01% |
+385
| New | +$183K |
|
11489
PUT
Caribou Biosciences
CRBU
$177M
| $31.8K | ﹤0.01% |
19,400
-52,800
| -73% | -$169K |
|
11490
CytomX Therapeutics
CTMX
$723M
| $31.6K | ﹤0.01% |
25,919
-910,859
| -97% | -$1.81M |
|
|
TUYA
11491
CALL
Tuya Inc
TUYA
$1.12B
| $31.5K | ﹤0.01% |
+18,400
| New | +$33.4K |
|
|
CLLS
11492
PUT
Cellectis
CLLS
$344M
| $31.4K | ﹤0.01% |
16,800
-14,100
| -46% | -$37K |
|
|
EDVA
11493
Endovia Health Sciences, Inc.
EDVA
$2.34M
| $31.3K | ﹤0.01% |
851
-18
| -2% | -$844 |
|
|
GRRR
11494
Gorilla Technology Group
GRRR
$425M
| $31.3K | ﹤0.01% |
11,296
+1,535
| +16% | +$8.18K |
|
|
MRSN
11495
PUT
DELISTED
Mersana Therapeutics
MRSN
| $31K | ﹤0.01% |
616
-4,828
| -89% | -$349K |
|
11496
Dominari Holdings
DOMH
$61.1M
| $30.9K | ﹤0.01% |
16,535
+4,397
| +36% | +$10.3K |
|
|
BQ
11497
Boqii Holding Ltd
BQ
$6.82M
| $30.7K | ﹤0.01% |
5,832
+1,364
| +31% | +$5.04K |
|
11498
PUT
Upland Software
UPLD
$13.3M
| $30.6K | ﹤0.01% |
1,230
-1,500
| -55% | -$39.5K |
|
|
GURE
11499
Gulf Resources
GURE
$6.35M
| $30.4K | ﹤0.01% |
+2,954
| New | +$42.9K |
|
|
NOTE
11500
CALL
DELISTED
FiscalNote
NOTE
| $30.4K | ﹤0.01% |
+1,733
| New | +$27.5K |
|
Similar funds
Jeff Yass's Q2 2024 Portfolio in Review
As of Q2 2024, Jeff Yass held 13,638 positions worth $537B, down 6.7% from $576B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass withdrew a net $65.7B in Q2 2024, closing 1,726 positions and reducing 5,607 holdings. Its most notable exit was iShares MSCI USA Quality Factor ETF, an estimated $26.2M position sold in full.
By sector, the portfolio is most concentrated in Technology at 2.4% of assets, down from 3% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jeff Yass opened a new position in NextEra Energy 7.299% Corporate Units worth $127M.
- Jeff Yass's largest Q2 2024 buy was NextEra Energy 7.299% Corporate Units: 2,575,000 shares worth $127M.
- Jeff Yass added most to Vanguard FTSE Developed Markets ETF in Q2 2024, an estimated $521M increase.
- Jeff Yass's biggest Q2 2024 reduction was NVIDIA, cutting an estimated $5.31B.
- Jeff Yass fully exited iShares MSCI USA Quality Factor ETF in Q2 2024, selling an estimated $26.2M.
- Jeff Yass's ten largest holdings make up 26% of its $537B portfolio in Q2 2024.
- Jeff Yass opened 1,591 new positions and closed 1,726 in Q2 2024.
- Jeff Yass's portfolio value fell 6.7% quarter-over-quarter to $537B.
Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.